Ftse Mib
34.819,74
-1,64%
DAX
18.768,96
0,33%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
69.662,18
5,11%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Alterity Therapeutics Limited (ATHE) Alterity Therapeutics Limited (ATHE) Notizie

ATHE

Alterity Therapeutics (ATHE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATHE
DataOraFonteTitoloSimboloCompagnia
08/05/202413:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewNASDAQ:ATHEAlterity Therapeutics Limited
30/04/202413:25GlobeNewswire Inc.Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
29/04/202413:25GlobeNewswire Inc.Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaNASDAQ:ATHEAlterity Therapeutics Limited
17/04/202413:25GlobeNewswire Inc.Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
10/04/202413:25GlobeNewswire Inc.Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024NASDAQ:ATHEAlterity Therapeutics Limited
26/03/202415:25GlobeNewswire Inc.Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
20/02/202416:25GlobeNewswire Inc.Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
15/02/202423:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
15/02/202423:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATHEAlterity Therapeutics Limited
06/02/202413:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewNASDAQ:ATHEAlterity Therapeutics Limited
29/01/202413:24GlobeNewswire Inc.Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekNASDAQ:ATHEAlterity Therapeutics Limited
22/01/202413:25GlobeNewswire Inc.Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesNASDAQ:ATHEAlterity Therapeutics Limited
21/12/202306:30GlobeNewswire Inc.Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerNASDAQ:ATHEAlterity Therapeutics Limited
04/12/202322:35GlobeNewswire Inc.Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressNASDAQ:ATHEAlterity Therapeutics Limited
04/12/202313:25GlobeNewswire Inc.Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s DiseaseNASDAQ:ATHEAlterity Therapeutics Limited
27/11/202313:25GlobeNewswire Inc.Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
16/11/202313:25GlobeNewswire Inc.Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434NASDAQ:ATHEAlterity Therapeutics Limited
08/11/202313:25GlobeNewswire Inc.Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
30/10/202312:25GlobeNewswire Inc.Appendix 4C – Q1 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
26/10/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATHEAlterity Therapeutics Limited
31/08/202313:25GlobeNewswire Inc.Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian DisorderNASDAQ:ATHEAlterity Therapeutics Limited
23/08/202313:25GlobeNewswire Inc.Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’sNASDAQ:ATHEAlterity Therapeutics Limited
22/08/202313:25GlobeNewswire Inc.Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:ATHEAlterity Therapeutics Limited
15/08/202313:25GlobeNewswire Inc.Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
31/07/202313:52GlobeNewswire Inc.Appendix 4C – Q4 FY23 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
26/07/202313:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as PlannedNASDAQ:ATHEAlterity Therapeutics Limited
21/06/202313:25GlobeNewswire Inc.Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023NASDAQ:ATHEAlterity Therapeutics Limited
21/06/202312:09Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ATHEAlterity Therapeutics Limited
30/05/202313:25GlobeNewswire Inc.Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderNASDAQ:ATHEAlterity Therapeutics Limited
19/05/202313:25GlobeNewswire Inc.Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023NASDAQ:ATHEAlterity Therapeutics Limited
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATHE

La tua Cronologia

LSE
0MDK
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network